Supernus Pharmaceuticals and Indivior agreed to a “merger of equals” to create a CNS-focused company under the Supernus name. The transaction is structured as an all-stock deal with an expected close in the fourth quarter of 2026 and a one-time special cash dividend to Indivior shareholders prior to close. The combined company will bring a commercial portfolio spanning addiction, ADHD, depression, and Parkinson’s disease, including Indivior’s Sublocade, which recorded nearly $1 billion in sales over the 12 months ending June 30, 2026. The companies also cited structural synergies and forecast about $125 million in cost savings. The merger positions Supernus to scale execution across multiple CNS indications and adds a broader set of commercial assets while maintaining a concentrated therapeutic focus.